Premium
Apheresis for MPO‐ANCA‐associated RPGN—indications and efficacy: Lessons learned from Japan nationwide survey of RPGN
Author(s) -
Yamagata Kunihiro,
Hirayama Kouichi,
Mase Kaori,
Yamaguchi Naoto,
Kobayashi Masaki,
Takahashi Hideto,
Koyama Akio
Publication year - 2005
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.20035
Subject(s) - medicine , rapidly progressive glomerulonephritis , apheresis , surgery , gastroenterology , disease , vasculitis , platelet
Abstract A national survey concerning rapidly progressive glomerulonephritis (RPGN) was conducted in Japan between 1989 and 2000 and resulted in the registration of 715 patients with RPGN. Among the documented patients, the most frequent primary disease was primary pauci‐immune crescentic glomerulonephritis (n = 283), and the second most frequent was microscopic polyangitis (n = 127). Overall, 370 patients had MPO‐ANCA, and 23 patients had PR3‐ANCA. We found that both renal and patient survivals were significantly worse in patients with MPO‐ANCA‐associated RPGN than patients with PR3‐ANCA. Fifty‐three patients received apheresis therapy with various combinations of immunosuppressive regimens. They had higher serum creatinine, higher CRP, and a higher frequency of complicated pulmonary involvements as compared to the controls without apheresis therapy. In dialysis‐dependent patients, no additional benefit from apheresis therapy was observed. Only pulmonary renal syndrome patients with CRP > 6 mg/dl at presentation showed a slightly better prognosis (patient survival with apheresis; 66.7%, without apheresis; 56.7%). Furthermore, a rapid MPO‐ANCA titer reduction was observed in patients treated with apheresis. Patients with MPO‐ANCA‐associated RPGN were older, and had more chronic and sclerotic lesions than patients with PR3‐ANCA‐associated RPGN. Based on these findings, we suggest that a lower dose of immunosuppressant should be considered in order to avoid opportunistic infection. In this situation, cytapheresis is the treatment of choice. Nevertheless, in patients with an aggressive form of RPGN with rapid deterioration of renal function like the PR3‐ANCA‐associated RPGN, or pulmonary renal syndrome complicated severe inflammation, or relapses with high MPO‐ANCA titer, we conclude that apheresis therapy should be considered. J. Clin. Apheresis © 2005 Wiley‐Liss, Inc.